Cereno Scientific initiates collaboration with CRO partner OCT to conduct a phase II study

Cereno Scientific has signed a Letter of Intent with OCT about a collaboration to conduct a phase II study to investigate the antithrombotic effects of Cerenos candidate drug CS1.

“It is very gratifying that we pass another milestone and that we initiate a collaboration with OCT for our planned phase II clinical study. The company meets our strict requirements of experience and level of competence”, says Cereno Scientifics CEO Sten R. Sörensen.

Cereno Scientific is developing a new preventive drug that normalizes the body’s own defence system against blood clots to be used on the global market to prevent thrombosis. Following the recent news of positive milestone progress of the company’s candidate drug CS1, Cereno Scientific is gearing up for their clinical programme with CS1. The company will collaborate with OCT, a CRO who will be the partner for the phase II study.

"We are pleased to assist Cereno Scientific in the development of their innovative product. We hope that our partnership will provide the pharmaceutical market with a valuable drug which improves preventive therapy against thrombosis and improves the quality of life for patients. To achieve this, we are ready to apply our strong expertise and relationships with the leading investigational sites”, sais OCT President Dmitry Sharov.

About OCT
OCT is a full-service clinical CRO operational in Central and Eastern Europe and the US. In Russia, where their HQ is located, OCT is officially considered the leading contract research organization based on the number of clinical trials approved. With 9 offices in Eastern Europe and the US, OCT provides clinical research services to both Big Pharma and small or mid-sizes biotechnology companies – American, European and Asian.

Since 2005 when the company was founded, over 260 studies in diverse therapeutic areas and phases have been conducted by OCT team for over 100 Sponsors. With over 190 people on staff including local regulatory and logistics specialists, medical writers and biostatisticians, project managers and CRAs, OCT can successfully plan and perform a clinical study from scratch.

For more information, please visit www.oct-clinicaltrials.com

For more information, please contact:
Sten R. Sörensen – CEO

Tel: +46 733 74 03 74
E-mail sten.sorensen@cerenoscientific.com
www.cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is a controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.

This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on June 26th 2018.

Tags:

Subscribe

Documents & Links